Investigational drug · Phase 2
INCAGN02390
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Endometrial Cancer, Head and Neck Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
7
Any phase or sponsor naming "INCAGN02390"
First trial start
2020
Jul 27, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INCAGN02390", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Endometrial Cancer
- Head and Neck Cancer
Approved drugs for the same conditions: Melanoma · Head and neck cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INCAGN02390" as an intervention, largest first.
Incyte CorporationIncyte (INCY)
NCT04463771 · 206 participants · Start Jan 26, 2021 · Primary completion May 29, 2026
Drug: retifanlimab; epacadostat and 3 more · For: Endometrial Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 65 sites in all
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckPivotal-lookingCompleted
Incyte Biosciences International SàrlIncyte (INCY)
NCT05287113 · 176 participants · Start Nov 14, 2022 · Primary completion Mar 14, 2025
Drug: Retifanlimab; INCAGN02385 and 2 more · For: Head and Neck Cancer
Sites: Scottsdale, Arizona; Duarte, California; Irvine, California · 91 sites in all
Incyte CorporationIncyte (INCY)
NCT04370704 · 61 participants · Start Jul 27, 2020 · Primary completion Aug 25, 2025
Drug: INCAGN02385; INCAGN02390 and 1 more · For: Melanoma
Sites: Los Angeles, California; Miami, Florida; Tampa, Florida · 17 sites in all
Incyte CorporationIncyte (INCY)
NCT03652077 · 40 participants · Start Sep 24, 2018 · Primary completion Aug 18, 2021
Drug: INCAGN02390 · For: Cervical Cancer; Gastric Cancer; Stomach Cancer and 18 more
Sites: Los Angeles, California; Jackson, Mississippi; Hackensack, New Jersey · 4 sites in all
Incyte CorporationIncyte (INCY)
NCT04586244 · 30 participants · Start Jan 14, 2022 · Primary completion Jan 29, 2024
Drug: retifanlimab; epacadostat and 2 more · For: Urothelial Carcinoma
Sites: Iowa City, Iowa; Cincinnati, Ohio; Columbus, Ohio · 12 sites in all
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT06056895 · 12 participants · Start Nov 8, 2023 · Primary completion Jan 31, 2027
Drug: Retifanlimab; Tuparstobart and 1 more · For: Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Merkel Cell Carcinoma
Sites: Seattle, Washington
University of Alabama at BirminghamAcademic, hospital or other
NCT06290622 · 0 participants · Start Aug 30, 2024 · Primary completion Jun 30, 2026
Drug: Retifanlimab, INCAGN02385, INCAGN02390 · For: Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular
Newest research
PubMed records naming it or its code names, newest first.
- First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.
Gutierrez ME, Tang SC, Powderly JD, et al. · Oncologist 2025
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.